107 related articles for article (PubMed ID: 8523060)
1. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?
Boos J; Krümpelmann S; Schulze-Westhoff P; Euting T; Berthold F; Jürgens H
J Clin Oncol; 1995 Dec; 13(12):2954-60. PubMed ID: 8523060
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the variability of etoposide pharmacokinetics in children.
Boos J; Real E; Schulze-Westhof ; Wolff J; Euting T; Jürgens H
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):495-7. PubMed ID: 1490803
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
4. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
Méresse V; Vassal G; Michon J; De Cervens C; Courbon B; Rubie H; Perel Y; Landman J; Chastagnier P; De Valck C
J Clin Oncol; 1993 Apr; 11(4):630-7. PubMed ID: 8478658
[TBL] [Abstract][Full Text] [Related]
5. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin.
Relling MV; McLeod HL; Bowman LC; Santana VM
Clin Pharmacol Ther; 1994 Nov; 56(5):503-11. PubMed ID: 7955814
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
[TBL] [Abstract][Full Text] [Related]
7. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
8. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
[TBL] [Abstract][Full Text] [Related]
9. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
10. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation.
Rodman JH; Murry DJ; Madden T; Santana VM
J Clin Oncol; 1994 Nov; 12(11):2390-7. PubMed ID: 7964955
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
15. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Cairo MS; Siegel S; Anas N; Sender L
Cancer Res; 1989 Feb; 49(4):1063-6. PubMed ID: 2536292
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
Kunitoh H; Watanabe K
J Clin Oncol; 1994 Jan; 12(1):83-9. PubMed ID: 8270989
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
20. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma.
Campbell LA; Seeger RC; Harris RE; Villablanca JG; Matthay KK
J Clin Oncol; 1993 Apr; 11(4):623-9. PubMed ID: 8478657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
